The Oxford Antibiotic Group has outstanding expertise in drug design and development, and a large number of screening platforms for various indications.
In addition to OxAG’s in house research programs, the company operates a CRO business, which gives academic and industrial collaborators access to the platforms and the team’s expertise.
The services that are being offered, are as follows:
Medicinal chemistry and synthesis
Compound modification based on medicinal chemistry aspects to improve solubility, stability or ADME features. OxAG delivers the full project plan by developing with the partner the synthesis concept and the screening-based med-chem. program.
OxAG’s anti-infective high throughput screening platform contains more than 200 different MDR bacterial, fungal and viral strains. It complies with EUCAST standards.
C. elegans screening
OxAG’s C. elegans platform allows to screen for antibiotic activity, toxicity and age associated neurodegenerative disorders (Alzheimer´s disease, Parkinson´s diseases, Huntington disease and amyotrophic lateral sclerosis).
The toxicology screening platform allows OxAG to determine in HTS general toxicity (Alamar Blue, AnnexinV/PI, Caspase, MTT-Assay, hERG-Test) and genotoxic/ mutagenic activity of compounds (HPRT Assay, Comet Assay, Micronucleus Assay, Mitotic index).
In addition, the C. elegans-based toxicity platform is designed to give an indication of toxicity potential early in the product development pipeline in order to eliminate high-risk compounds without the need for testing in expensive vertebrate studies.